Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults

Thomas, Ben D. H.; Farquhar-Smith, Paul

doi:10.2147/tcrm.s50212

Cited by 8 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 53 ] Specifically, it has been increasingly utilized for the relief of PHN in recent years, demonstrating both safety and efficacy. [ 54 ] For “prevention,” the prevention of PHN has been a prominent area of research in recent years, with a focus on interventions such as vaccination, [ 55 ] gabapentinoids, [ 56 ] epidural block. [ 57 ] For “herpes zoster,” the occurrence of PHN is causally associated with HZ.…”

Section: Discussionmentioning

confidence: 99%

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

He,

Miao

et al. 2023

Medicine

View full text Add to dashboard Cite

Postherpetic neuralgia (PHN) represents a notable clinical challenge as it is the most prevalent and severe complication of herpes zoster (HZ). The primary objective was to investigate the current research status and hotspots of PHN research during the period from 2000 to 2022. The literature pertaining to PHN was gathered through the utilization of the Web of Science Core Collection, spanning from January 2000 to December 2022. The software, CiteSpace version 6.2.R2, was employed to produce visual depictions of publications related to PHN across various dimensions such as year, country/region, institution, journal, author, keyword, and reference. This study involved a total of 3505 papers. The USA held a dominant position in the production of scholarly articles. Argentina exhibited the highest frequency of participation in international collaboration. Out of all the institutions, Pfizer exhibited the highest degree of productivity. Harvard University exhibited the highest frequency of participation in international collaboration. The Pain exhibited the most noteworthy productivity rate and citation count among all other journals. Ralf Baron was identified as the most productive author, whereas DWORKIN RH attained the highest citation count. Contemporary scholarly investigations are predominantly centered on identifying risk factors, devising preventative measures, and exploring novel and secure methods of pain management. The current investigation has revealed the focal areas and patterns of studies pertaining to PHN. Presently, the research in this field is focused on identifying the risk factors and preventive measures for PHN, alongside exploring novel and secure pain management strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

He,

Miao

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…37 Direct comparisons between the two formulations have not been performed, and it is unknown whether gabapentin enacarbil has better efficacy in PHN management than the immediate-release formulation of gabapentin. 39 …”

Section: Management Of Phnmentioning

confidence: 99%

Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology

Mallick-Searle¹,

Snodgrass²,

Brant³

2016

JMDH

147

109

View full text Add to dashboard Cite

Herpes zoster, also known as shingles, is a distinctive clinical condition caused by the reactivation of latent varicella zoster (chickenpox) virus following an initial infection. Approximately 1 million cases of herpes zoster occur annually in the US, and one in every three people develops herpes zoster during their lifetime. Postherpetic neuralgia is a neuropathic pain syndrome characterized by pain that persists for months to years after resolution of the herpes zoster rash. It stems from damage to peripheral and central neurons that may be a byproduct of the immune/inflammatory response accompanying varicella zoster virus reactivation. Patients with postherpetic neuralgia report decreased quality of life and interference with activities of daily living. Approaches to management of postherpetic neuralgia include preventing herpes zoster through vaccination and/or antiviral treatment, and administering specific medications to treat pain. Current guidelines recommend treatment of postherpetic neuralgia in a hierarchical manner, with calcium channel α2-δ ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line drugs. The safety and tolerability of pharmacologic therapies for pain are important issues to consider as postherpetic neuralgia affects primarily an older population. Patients should be educated on appropriate dosing, titration if applicable, the importance of adherence to treatment for optimal effectiveness, and possible side effects. Health-care professionals play a key role in helping to ameliorate the pain caused by postherpetic neuralgia through early recognition and diligent assessment of the problem; recommending evidence-based treatments; and monitoring treatment adherence, adverse events, responses, and expectations. Nurse practitioners are especially crucial in establishing communication with patients and encouraging the initiation of appropriate pain-relieving treatments.

show abstract

Post-herpetic Neuralgia: a Review

Hadley

Gayle

Ripoll

et al. 2016

Curr Pain Headache Rep

114

142

View full text Add to dashboard Cite

Post-herpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists 3 months or more following an outbreak of shingles. Shingles, also known as acute herpes zoster, is associated with the reactivation of the dormant varicella zoster virus in an individual who has experienced chicken pox. PHN is associated with persistent and often refractory neuropathic pain. Patients may experience multiple types of pain including a constant deep, aching, or burning pain; a paroxysmal, lancinating pain; hyperalgesia (painful stimuli are more painful than expected); and allodynia (pain associated with typically non-painful stimuli). The pharmacological treatment of PHN may include a variety of medications including alpha-2 delta ligands (gabapentin and pregabalin), other anticonvulsants (carbamazepine), tricyclic antidepressants (amitriptyline, nortriptyline, doxepin), topical analgesics (5 % lidocaine patch, capsaicin) tramadol, or other opioids. The considerable side effect profiles of the commonly used oral medications often limit their practical use, and a combination of both topical and systemic agents may be required for optimal outcomes. Physicians and other treatment providers must tailor treatment based on the response of individual patients.

show abstract

Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults

Cited by 8 publications

References 23 publications

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology

Post-herpetic Neuralgia: a Review

Contact Info

Product

Resources

About